Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by M. Roden
Total Records ( 7 ) for M. Roden
  G Kacerovsky Bielesz , M Chmelik , C Ling , R Pokan , J Szendroedi , M Farukuoye , M Kacerovsky , A. I Schmid , S Gruber , M Wolzt , E Moser , G Pacini , G Smekal , L Groop and M. Roden

We tested the hypothesis that short-term exercise training improves hereditary insulin resistance by stimulating ATP synthesis and investigated associations with gene polymorphisms.


We studied 24 nonobese first-degree relatives of type 2 diabetic patients and 12 control subjects at rest and 48 h after three bouts of exercise. In addition to measurements of oxygen uptake and insulin sensitivity (oral glucose tolerance test), ectopic lipids and mitochondrial ATP synthesis were assessed using1H and31P magnetic resonance spectroscopy, respectively. They were genotyped for polymorphisms in genes regulating mitochondrial function, PPARGC1A (rs8192678) and NDUFB6 (rs540467).


Relatives had slightly lower (P = 0.012) insulin sensitivity than control subjects. In control subjects, ATP synthase flux rose by 18% (P = 0.0001), being 23% higher (P = 0.002) than that in relatives after exercise training. Relatives responding to exercise training with increased ATP synthesis (+19%, P = 0.009) showed improved insulin sensitivity (P = 0.009) compared with those whose insulin sensitivity did not improve. A polymorphism in the NDUFB6 gene from respiratory chain complex I related to ATP synthesis (P = 0.02) and insulin sensitivity response to exercise training (P = 0.05). ATP synthase flux correlated with O2uptake and insulin sensitivity.


The ability of short-term exercise to stimulate ATP production distinguished individuals with improved insulin sensitivity from those whose insulin sensitivity did not improve. In addition, the NDUFB6 gene polymorphism appeared to modulate this adaptation. This finding suggests that genes involved in mitochondrial function contribute to the response of ATP synthesis to exercise training.

  K. Kempf , G. Manzo , P. Hanifi-Moghaddam , S. Kappler , J. Seissler , C. Jaeger , B. Boehm , M. Roden , H. Kolb , S. Martin and N. C. Schloot
  Not available
  D. Ziegler , N. Papanas and M. Roden
  Aims  To examine the sensitivity and specificity of three cut-off points of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction in patients within the first year after diagnosis of diabetes.

Methods  Neuropad results were read at 10, 15 and 20 min and evaluated for diagnostic utility in distal symmetric polyneuropathy confirmed by electrophysiology and small-fibre dysfunction in 52 patients with Type 1 diabetes and 99 patients with Type 2 diabetes.

Results  The prevalence of distal symmetric polyneuropathy was 15.4% in Type 1 diabetes and 43.4% in Type 2 diabetes, while that of small-fibre dysfunction was 9.6 and 31.3%, respectively. Sensitivity of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction was highest in Type 1 diabetes for the 10-min threshold reaching 87.5 and 80.0%, respectively, while it was modestly high in Type 2 diabetes at 65.1 and 67.7%, respectively. Specificity in both diabetes types was modest for the 10-min threshold (44.7-48.2%). It was highest for the 20-min threshold (83.8-89.3%) at the cost of poor sensitivity at 12.5-34.9%. Negative predictive values were relatively high for all three cut-off points in both types of diabetes (64.1-97.1%) at the cost of poor positive predictive values at 12.5-71.4%.

Conclusions  In patients within the first year after diagnosis of diabetes, the 10-min cut-off for Neuropad provides a relatively high sensitivity and modest specificity for distal symmetric polyneuropathy and small-fibre dysfunction, rendering the test more suitable as a screening tool than the 15- and 20-min cut-offs.

  B. Nowotny , P. J. Nowotny , K. Strassburger and M. Roden
  Aims  Assessment of insulin sensitivity by dynamic metabolic tests such as the hyperinsulinemic euglycemic clamp critically relies on the reproducible and fast measurement of blood glucose concentrations. Although various instruments have been developed over the last decades, little is known as to the accuracy and comparability. We therefore compared the best new instrument with the former gold standard instruments to measure glucose concentrations in metabolic tests.

Methods  Fasting blood samples of 15 diabetic and 10 healthy subjects were collected into sodium-fluoride tubes, spiked with glucose (0, 2.8, 6.9 and 11.1 mmol/l) and measured either as whole blood (range 3.3-26.3 mmol/l) or following centrifugation as plasma (range 3.9-32.0 mmol/l). Plasma samples were analyzed in the YSI-2300 STAT plus (YSI), EKF Biosen C-Line (EKF) and the reference method, Beckman Glucose analyzer-II (BMG), whole blood samples in EKF instruments with YSI as reference method.

Results  The average deviation of the EKF from the reference, BMG, was 3.0 ± 3.5% without any concentration-dependent variability. Glucose measurements by YSI were in good agreement with that by BMG (plasma) and EKF (plasma and whole blood) up to concentrations of 13.13 mmol/l (0.5 ± 3.7%), but deviation increased to −6.2 ± 3.8% at higher concentrations. Precision (n = 6) was ±2.2% (YSI), ±3.9% (EKF) and ±5.2% (BMG).

Conclusions  The EKF instrument is comparable regarding accuracy and precision to the reference method BMG and can be used in metabolic tests, while the YSI showed a systematic shift at higher glucose concentrations. Based on these results we decided to replace BMG with EKF instrument in metabolic tests.

  A. Tura , G. Pacini , Y. Winhofer , L. Bozkurt , G. Di Benedetto , U. Morbiducci , M. Roden and A. Kautzky-Willer
  Aims  Women with former gestational diabetes are at increased risk of Type 2 diabetes, which likely relates to hyperlipidaemia and ectopic lipid storage, mainly in the liver. Here, we examined the response of non-esterified fatty acid dynamics to oral glucose loading (oral glucose tolerance test).

Methods  We studied women with former gestational diabetes with normal glucose tolerance (n = 60) or impaired glucose metabolism (n = 12) and compared them with healthy women after normal pregnancy (control subjects, n = 15). During a 3-h oral glucose tolerance test, glucose, insulin and non-esterified fatty acid were frequently measured to compute the area under the non-esterified fatty acid curve and parameters of β-cell function and insulin sensitivity. Through mathematical modelling, we assessed insulin sensitivity of lipolysis inhibition and the fractional non-esterified fatty acid turnover rate. We also measured some serum liver enzymes.

Results  Women with former gestational diabetes were slightly older and had greater body mass than control subjects. Subjects with impaired glucose metabolism had lower oral glucose insulin sensitivity, but higher fasting insulin and area under the non-esterified fatty acid curve, which inversely related to oral glucose insulin sensitivity and independently determined mean glycaemia. Model-derived non-esterified fatty acid parameters were lower in subjects with impaired glucose metabolism than in control subjects, particularly sensitivity of non-esterified fatty acid inhibition to insulin (2.50 ± 0.52 vs. 1.06 ± 0.20.10−2 ml/μU). Also, subjects with impaired glucose metabolism had higher liver transaminases. However, all non-esterified fatty acid parameters showed only modest inverse correlation with liver transaminases.

Conclusions  Despite greater insulinaemia, circulating non-esterified fatty acids are higher in women with former gestational diabetes than in control subjects, which likely results from reduced sensitivity of lipolysis inhibition to insulin. This parameter may serve as indicator of an early metabolic derangement in this population at risk for diabetes.

  M. N. Pham , M. I. Hawa , M. Roden , G. Schernthaner , P. Pozzilli , R. Buzzetti , W. A. Scherbaum , J. Seissler , S. Hunter , R. D. G. Leslie , H. Kolb and N. C. Schloot
  Aims  Systemic concentrations of adhesion molecules and chemokines are associated with increased risk of cardiovascular complications. We compared these factors between patients with Type 2 diabetes vs. Type 1 diabetes or latent autoimmune diabetes in adults.

Methods  Serum concentrations of adhesion molecules sE-selectin, sICAM-1 and sVCAM-1, and chemokines CCL2, CCL3 and CCL4 were measured in 61 patients with latent autoimmune diabetes in adults, 90 with Type 1 diabetes, 465 with Type 2 diabetes and in 41 control subjects, using multiple regression models to adjust for possible confounders.

Results  Patients with Type 2 diabetes exhibited greater concentrations of adhesion molecules (< 0.02) than those with Type 1 diabetes, latent autoimmune diabetes in adults and control subjects. These differences persisted upon adjustments for age, sex, BMI, blood pressure and diabetes duration (< 0.04). Higher BMI positively correlated with concentrations of adhesion molecules in all subjects (< 0.0001). Concentrations of sE-selectin positively related to diastolic (β = 0.31) and systolic (β = 0.28) blood pressure in the adjusted model (< 0.04). Concentrations of the chemokines, CCL2 and CCL4, did not differ between groups, while CCL3 was higher in patients with latent autoimmune diabetes in adults and Type 1 diabetes than in those with Type 2 diabetes and control subjects (< 0.05).

Conclusions  Systemic concentrations of adhesion molecules, but not chemokines, relate to cardiovascular risk factors, but remain higher after adjustments in Type 2 diabetes, suggesting a diabetes-type specific effect without difference between latent autoimmune diabetes in adults and Type 1 diabetes, despite their dissimilar phenotype.

  J. Genz , B. Haastert , H. Muller , F. Verheyen , D. Cole , W. Rathmann , B. Nowotny , M. Roden , G. Giani , A. Mielck , C. Ohmann and A. Icks
  Aims  To compare the effect of our newly developed online evidence-based patient information vs. standard patient information about sub-threshold elevated blood glucose levels and primary prevention of diabetes on informed patient decision making.

Methods  We invited visitors to the cooperating health insurance company, Techniker Krankenkasse, and the German Diabetes Center websites to take part in a web-based randomized controlled trial. The population after randomization comprised 1120 individuals aged between 40 and 70 years without known diabetes, of whom 558 individuals were randomly assigned to the intervention group receiving evidence-based patient information, and 562 individuals were randomly assigned to the control group receiving standard information from the Internet. The primary endpoint was acquired knowledge of elevated blood glucose level issues and the secondary outcomes were attitude to metabolic testing, intention to undergo metabolic testing, decisional conflict and satisfaction with the information.

Results  Overall, knowledge of elevated glucose level issues and the intention to undergo metabolic testing were high in both groups. Participants who had received evidence-based patient information, however, had significantly higher knowledge scores. The secondary outcomes in the evidence-based patient information subgroup that completed the 2-week follow-up period yielded significantly lower intention to undergo metabolic testing, significantly more critical attitude towards metabolic testing and significantly higher decisional conflict than the control subgroup (n = 466). Satisfaction with the information was not significantly different between both groups.

Conclusions  Evidence-based patient information significantly increased knowledge about elevated glucose levels, but also increased decisional conflict and critical attitude to screening and treatment options. The intention to undergo metabolic screening decreased. Future studies are warranted to assess uptake of metabolic testing and satisfaction with this decision in a broader population of patients with unknown diabetes.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility